

CADTH RAPID RESPONSE REPORT: REFERENCE LIST

# Stem Cell Transplant for Multiple Sclerosis: Clinical Effectiveness, Cost- Effectiveness, and Guidelines

Service Line:	Rapid Response Service
Version:	1.0
Publication Date:	November 13, 2020
Report Length:	8 Pages

**Authors:** Thyna Vu, Charlene Argáez

**Cite As:** *Stem Cell Transplant for Multiple Sclerosis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines*. Ottawa: CADTH; 2020 Nov. (CADTH rapid response report: reference list).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

## Research Questions

1. What is the clinical effectiveness of stem cell transplant for individuals with multiple sclerosis?
2. What is the cost-effectiveness of stem cell transplant for individuals with multiple sclerosis?
3. What are the evidence-based guidelines regarding stem cell transplant for individuals with multiple sclerosis?

## Key Findings

Two randomized controlled trials and one non-randomized study were identified regarding the clinical effectiveness of stem cell transplant for individuals with multiple sclerosis. One systematic review was identified regarding the cost-effectiveness of stem cell transplant for individuals with multiple sclerosis. Four evidence-based guidelines were identified regarding stem cell transplant for individuals with multiple sclerosis.

## Methods

### Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including Medline and EMBASE via OVID, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were stem cell transplant and multiple sclerosis. Filters were applied to limit the retrieval to health technology assessments, systematic reviews, and meta analyses, randomized controlled trials, and non-randomized studies, economic studies, and guidelines. The search was also limited to English language documents published between January 1, 2015 and November 9, 2020. Internet links are provided where available.

### Selection Criteria

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed. Open access full-text versions of evidence-based guidelines were reviewed when abstracts were not available.

**Table 1: Selection Criteria**

<b>Population</b>	Individuals with multiple sclerosis
<b>Intervention</b>	Autologous hematopoietic stem cell transplant (HSCT)
<b>Comparator</b>	Q1-Q2: Standard of care (i.e., disease modifying therapy) Q3: Not applicable
<b>Outcomes</b>	Q1: Clinical effectiveness (e.g., disability, progression free survival, quality of life, pain, treatment-related mortality) Q2: Cost-effectiveness (e.g., cost per quality-adjusted life-year gained) Q3: Recommendations regarding best practices
<b>Study Designs</b>	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, economic evaluations, evidence-based guidelines

## Results

Two randomized controlled trials<sup>2,3</sup> and one non-randomized study<sup>4</sup> were identified regarding the clinical effectiveness of stem cell transplant for individuals with multiple sclerosis. One systematic review was identified regarding the cost-effectiveness of stem cell transplant for individuals with multiple sclerosis.<sup>1</sup> Four evidence-based guidelines<sup>5-8</sup> were identified regarding stem cell transplant for individuals with multiple sclerosis. No health technology assessments or economic evaluations were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in the appendix.

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

1. Nagpal A, Milte R, Kim SW, et al. Economic evaluation of stem cell therapies in neurological diseases: a systematic review. *Value Health*. 2019 Feb;22(2):254-262. [PubMed: PM30711072](#)

### Randomized Controlled Trials

2. Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. *JAMA*. 2019 Feb;321(2):165-174. [PubMed: PM30644983](#)
3. Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. *Neurology*. 2015 Mar 10;84(10):981-988. [PubMed: PM25672923](#)

### Non-Randomized Studies

4. Mariottini A, Innocenti C, Forci B, et al. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. *Eur J Neurol*. 2019 Apr;26(4):624-630. [PubMed: PM30414315](#)

### Economic Evaluations

No literature identified.

### Guidelines and Recommendations

5. Miller AE, Chitnis T, Cohen BA, et al. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. *JAMA Neurology*. 2020 Oct 26. [PubMed: PM33104165](#)

6. Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). *Bone Marrow Transplant*. 2020 Feb;55(2):283-306.  
[PubMed: PM31558790](#)
7. Cohen JA, Baldassari LE, Atkins HL, et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019 May;25(5):845-854.  
[PubMed: PM30794930](#)
8. Healthcare Improvement Scotland. Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding to high efficacy disease modifying therapies [*SHGT advice statement 07-19*]. Edinburgh, Scotland: Healthcare Improvement Scotland; 2019 Oct:  
[http://www.healthcareimprovementscotland.org/our\\_work/technologies\\_and\\_medicines/topics\\_assessed/shtg\\_07-19.aspx](http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/topics_assessed/shtg_07-19.aspx) Accessed 2020 Nov 11.  
*See: Advice for NHSScotland (p1); Clinical Effectiveness – Guidelines (p9-10).*

## Appendix — Further Information

### Systematic Reviews and Meta-analyses

#### Comparator – No Comparison Group Specified

9. Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. *Bone Marrow Transplant.* 2020 Oct;55(10):1928-1934.  
[PubMed: PM32020080](#)
10. Ge F, Lin H, Li Z, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. *Neurol Sci.* 2019 Mar;40(3):479-487.  
[PubMed: PM30535563](#)
11. Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. *Neurology.* 2017 May 30;88(22):2115-2122.  
[PubMed: PM28455383](#)

#### Guidelines – Methods Not Specified

12. Alberta Health Services. Alberta bone marrow and blood cell transplant program: standard practice manual. Edmonton (AB): Cancer Control Alberta, Alberta Health Services; 2020 Oct (*updated*):  
<https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-bmt-manual.pdf> Accessed 2020 Nov 11.  
*See: Multiple Sclerosis - Selection Criteria for Autologous Hematopoietic Stem Cell Transplant in MS.*
13. Welsh Health Specialised Services Committee. Haematopoietic Stem Cell Transplantation (HSCT) for adults [*Specialised services policy position PP142*]. Pontypridd, Wales: NHS Wales; 2020 Jan:  
<http://www.whssc.wales.nhs.uk/sitesplus/documents/1119/PP142%20HSCT%20v1.01.pdf> Accessed 2020 Nov 11.  
*See: 1.5 What NHS Wales has decided (p8).*
14. Zephir H, Puyade M, Gueguen A, et al. [Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis]. *Bull Cancer.* 2019 Jan;106(Suppl 1):S92-S101.  
[PubMed: PM30527815](#)

15. Coles A, Price S, Giavannoni G, et al. Treatment algorithm for multiple sclerosis disease-modifying therapies. London, England: NHS England; 2018 Sep: <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2019/03/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf> Accessed 2020 Nov 11.  
See: *Flowchart 12. Treatment algorithm for disease activity on second-line therapy, and note 14 (p10).*
16. Laureys G, Willekens B, Vanopdenbosch L, et al. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. *Acta Neurol Belg.* 2018 Jun;118(2):161-168.  
[PubMed: PM29536270](#)

## Review Articles

17. Bose G, Thebault SDX, Atkins HL, Freedman MS. Does resetting the immune system fix multiple sclerosis? *Can J Neurol Sci.* 2020 Jan;47(1):1-10.  
[PubMed: PM31511117](#)
18. Lycke J, Lenhoff S. Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. *Ther Adv Neurol Disord.* 2020 Jun;13:1756286420929467.  
[PubMed: PM32636931](#)
19. Mariottini A, De Matteis E, Muraro PA. Haematopoietic stem cell transplantation for multiple sclerosis: current status. *Biodrugs.* 2020 Jun;34(3):307-325.  
[PubMed: PM32166703](#)
20. Dunn-Pirio AM, Heyman BM, Kaufman DS, Kinkel RP. Outcomes and cost-effectiveness of autologous hematopoietic cell transplant for multiple sclerosis. *Curr Treat Options Neurol.* 2019 Oct;21(10):53.  
[PubMed: PM31624926](#)
21. Gavriilaki M, Sakellari I, Gavriilaki E, Kimiskidis VK, Anagnostopoulos A. Autologous hematopoietic cell transplantation in multiple sclerosis: changing paradigms in the era of novel agents. *Stem Cells Int.* 2019 Jun;2019:5840286.  
[PubMed: PM31341484](#)
22. Ismail A, et al. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. *Curr Opin Support Palliat Care.* 2019 Dec;13(4):394-401.  
[PubMed: PM31599815](#)
23. Macaron G, Feng J, Moodley M, Rensel M. Newer treatment approaches in pediatric-onset multiple sclerosis. *Curr Treat Options Neurol.* 2019 Sep 27;21(10):50.  
[PubMed: PM31560095](#)
24. Atkins HL, Freedman MS. Five questions answered: a review of autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. *Neurotherapeutics.* 2017 Oct;14(4):888-893.  
[PubMed: PM28822119](#)

25. Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. *Nat Rev Neurol.* 2017 Jul;13(7):391-405.  
[PubMed: PM28621766](#)